The Smith & Nephew share price is on the move, here’s why

I’ve been watching the Smith & Nephew share price for a while as the medical tech giant shows some real potential. So is now the time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE:SN.), the global medical technology giant, has been on a tear in the market of late. With a history dating back to 1856, this company has proved its ability to adapt and thrive in the ever-evolving healthcare sector. But what’s behind the recent movement in the Smith & Nephew share price? Let’s dive into the latest earnings report and see why investors are taking notice.

Earnings report

The company’s second-quarter results for 2024 show some promising signs. Revenue reached $1.4bn, representing a 5.6% increase compared to the same period last year. This growth was driven by strong performances across multiple segments. Orthopaedics was up 5.8%, with notable rises in Hip and Knee Implants outside the US. Sports Medicine & ENT showed robust 7.6% increases, despite difficulties from China’s sports medicine volume-based procurement initiative. Advanced Wound Management returned to profit with a 3.3% increase, with all segments contributing positively.

It seems like the company’s focus on efficiency and productivity is paying off. The trading profit margin expanded to a healthy 16.7% in the first half of 2024, up from 15.3% in the same period last year. This improvement reflects some really positive results from the company’s 12-point plan for growth. Notably, the firm has significantly improved its cash flow. Trading cash flow jumped to 60%, compared to just 26% in 2023. This resulted in an impressive doubling of trading cash flow to more than $284m.

Building for the future

Management continues to invest heavily in innovation, which is crucial for maintaining a competitive edge. Recent product launches and enhancements include the expansion of the CORI Surgical System (now recognised as a leader in robotics-assisted surgery), full commercial launch of the AETOS Shoulder System targeting one of the fastest-growing segments in Orthopaedics, and US regulatory approval for the new CATALYSTEM Hip System. These innovations are expected to drive profits in the coming years, especially as demographics show the market for such products growing steadily.

In the latest report, management has maintained its 2024 guidance. The company expects underlying revenue growth between 5% and 6%, with a trading profit margin of at least 18%. The market seems to be responding positively to these developments. With the shares up more than 20% in the last month alone, investors appear to be recognising the potential in the recent turnaround efforts.

While the overall picture looks promising, it’s important to note that many challenges remain. The company is still working to improve inconsistent performance in US Hip and Knee Implants.

Furthermore, as a global company, management must manage supply chain complexities and potential disruptions, especially in light of recent global events that have highlighted the vulnerabilities in international trade and logistics.

One for the watchlist

The firm’s latest earnings report suggests steady progress towards the long-term turnaround strategy laid out in previous reports. With strong revenue growth, expanding margins, and a focus on innovation, I feel that the business is well-positioned for future success.

For those looking to build positions in the healthcare sector and in FTSE 100 companies with global reach, I think the stock warrants a closer look. As the business continues to innovate and expand its market presence, I’ll definitely be keeping it on my own watchlist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Gordon Best has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

I asked ChatGPT to name the FTSE 250 share it would buy in a heartbeat – and it went mad!

Harvey Jones wondered whether artificial intelligence was up to the job of finding him a brilliant FTSE 250 share to…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Is the BP share price primed for lift off?

As an activist investor takes a substantial holding in BP, Andrew Mackie assesses what it will take to energise the…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

No savings? I’m using the 5-step Warren Buffett method as I aim to get rich

Christopher Ruane outlines a handful of investment techniques he uses, inspired by the incredible stock market record of Warren Buffett.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With a spare £3,000, here’s how a new investor could start buying shares

Our writer explains how someone with a few thousand pounds and no prior stock market experience could start buying shares…

Read more »

UK money in a Jar on a background
Investing Articles

£10,000 invested in Greggs shares in 2020 has made this much passive income…

Greggs shares have struggled lately due to economic weakness and rising costs. Are they still worth considering for an ISA…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Don’t look now, but the FTSE 100’s beating the S&P 500 in 2025…

So far this year, UK stocks have been doing better than their US counterparts. So is the FTSE 100 the…

Read more »

Investing Articles

How much would someone need in UK shares to earn £5,000 in passive income each month?

Thousands of Stocks and Shares ISA investors have built up more than a million pounds and can sit back and…

Read more »

Investing Articles

£10,000 invested in Tesla stock 1 month ago is now worth…

Tesla stock is remarkably volatile for a mega-cap company. While this presents some opportunities for investors, it’s also inherently risky.

Read more »